JP2023533452A - 動脈瘤を処置するための求電子化合物および求電子プロドラッグ - Google Patents

動脈瘤を処置するための求電子化合物および求電子プロドラッグ Download PDF

Info

Publication number
JP2023533452A
JP2023533452A JP2022579739A JP2022579739A JP2023533452A JP 2023533452 A JP2023533452 A JP 2023533452A JP 2022579739 A JP2022579739 A JP 2022579739A JP 2022579739 A JP2022579739 A JP 2022579739A JP 2023533452 A JP2023533452 A JP 2023533452A
Authority
JP
Japan
Prior art keywords
aneurysm
alkyl
carbon
hydrogen
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022579739A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023533452A5 (https=
Inventor
フランシスコ ジェイ． ショップファー，
ブルース エー． フリーマン，
ヤン ジャオ，
ユーチン イー． チェン，
ジーフェン ジャン，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Pittsburgh
Original Assignee
University of Pittsburgh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Pittsburgh filed Critical University of Pittsburgh
Publication of JP2023533452A publication Critical patent/JP2023533452A/ja
Publication of JP2023533452A5 publication Critical patent/JP2023533452A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A61K31/231—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having one or two double bonds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/04—Nitro compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/201—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2022579739A 2020-06-23 2021-04-20 動脈瘤を処置するための求電子化合物および求電子プロドラッグ Pending JP2023533452A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063042707P 2020-06-23 2020-06-23
US63/042,707 2020-06-23
PCT/US2021/028175 WO2021262298A1 (en) 2020-06-23 2021-04-20 Electrophilic compounds and electrophilic prodrugs for treating aneurysm

Publications (2)

Publication Number Publication Date
JP2023533452A true JP2023533452A (ja) 2023-08-03
JP2023533452A5 JP2023533452A5 (https=) 2024-05-01

Family

ID=79281621

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022579739A Pending JP2023533452A (ja) 2020-06-23 2021-04-20 動脈瘤を処置するための求電子化合物および求電子プロドラッグ

Country Status (5)

Country Link
US (1) US20230241019A1 (https=)
EP (1) EP4167977A4 (https=)
JP (1) JP2023533452A (https=)
CA (1) CA3186710A1 (https=)
WO (1) WO2021262298A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3167273A1 (en) * 2020-03-19 2021-09-23 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Stabilization of compounds as cyclodextrin complexes

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090215895A1 (en) * 2004-01-30 2009-08-27 Peplin Biolipids Pty Ltd Therapeutic and carrier molecules
MX2009013937A (es) * 2007-07-02 2010-04-30 Entress Ab Nuevo uso de compuestos quimicos farmacologicamente activos conocidos.
DE102011103948A1 (de) * 2011-06-06 2012-12-06 B. Braun Melsungen Ag Biopassivierende Beschichtung von Gefäßprothesen mit Nitrocarbonsäuren enthaltenden Phospholipiden
EP3097911B8 (en) * 2014-01-24 2024-07-10 Noster Inc. Metabolism-improving agent comprising rare fatty acid
US10765652B2 (en) * 2016-10-05 2020-09-08 University of Pittsburgh—of the Commonwealth System of Higher Education Reversible nitroxide derivatives of nitroalkenes that mediate nitrosating and alkylating reactions
WO2020081957A1 (en) * 2018-10-19 2020-04-23 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Magnetic delivery system and hydrogel fixative for therapeutic cells
CA3167273A1 (en) * 2020-03-19 2021-09-23 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Stabilization of compounds as cyclodextrin complexes
US20230321179A1 (en) * 2020-08-18 2023-10-12 The Regents Of The University Of Michigan N-acyl amino acid products and uses

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
J. NEUROINFLAMMATION, vol. 16, no. 185, JPN6025014770, 2019, ISSN: 0005570420 *
OXID. MED. CELL. LONGEV., vol. 2019, JPN6025014771, 2019, pages 9372182, ISSN: 0005570421 *

Also Published As

Publication number Publication date
US20230241019A1 (en) 2023-08-03
WO2021262298A1 (en) 2021-12-30
CA3186710A1 (en) 2021-12-30
EP4167977A4 (en) 2024-07-10
EP4167977A1 (en) 2023-04-26

Similar Documents

Publication Publication Date Title
US20230255995A1 (en) Nicotinyl Riboside Compounds and Their Uses
US20220000824A1 (en) Treatment of pulmonary arterial hypertension using therapeutically effective oral doses of 10-nitro-9(e)-octadec-9-enoic acid
ES2865505T3 (es) Composiciones y métodos para tratar la hiperpermeabilidad intestinal
KR102537043B1 (ko) 조합 치료요법용 약학 조성물
KR20190122806A (ko) 조합 치료요법용 약학 조성물
Basivireddy et al. Indomethacin-induced free radical-mediated changes in the intestinal brush border membranes
US20250367229A1 (en) Treatment of Immune-Related Disorders, Kidney Disorders, Liver Disorders, Hemolytic Disorders, and Oxidative Stress-Associated Disorders Using NRH, NARH and Reduced Derivatives Thereof
JP2023533452A (ja) 動脈瘤を処置するための求電子化合物および求電子プロドラッグ
JP7656922B2 (ja) Ｒａｄ５１阻害薬としての求電子剤および求電子剤プロドラッグ
WO2015181135A1 (en) Skin cancer treatment
JP2023184678A (ja) 皮膚線維症を処置するための組成物および方法
WO2019006384A1 (en) TREATMENT OF ANEVRISM
US12280047B2 (en) Treatment of aneurysms
WO2025240850A1 (en) Nitroalkene-based inhibitors to target sting-dependent inflammation
Jiao et al. Crucial Role of STAT6 Signaling in Renal Fibrosis: PO0603
Mori et al. Inhibition of KIM-1-Mediated Fatty Acid Uptake by a Novel Inhibitor Attenuates Pro-Fibrotic Responses in Multiple Models of Human Primary Kidney Epithelial Cells Including Kidney Tubuloids: PO0601

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240418

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240418

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250411

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20250411

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250708

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250911

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250926

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20251215